Literature DB >> 18640947

Dose selection in phase I studies: why we should always go for the most effective.

Ian E Haines.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18640947     DOI： 10.1200/JCO.2008.17.6719

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Authors:  Daniela Bumbaca; Hong Xiang; C Andrew Boswell; Ruediger E Port; Shannon L Stainton; Eduardo E Mundo; Sheila Ulufatu; Anil Bagri; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; Ben-Quan Shen
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Maximum tolerated dose: clinical endpoint for a bygone era?

Authors:  Chris H Takimoto
Journal:  Target Oncol       Date:  2009-04-18       Impact factor: 4.493

Review 3.  Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?

Authors:  Daniel Crona; Federico Innocenti
Journal:  Biomark Med       Date:  2012-06       Impact factor: 2.851

4.  Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.

Authors:  Rajul K Jain; J Jack Lee; David Hong; Maurie Markman; Jing Gong; Aung Naing; Jennifer Wheler; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Authors:  Victoria K Woodcock; Sally Clive; Richard H Wilson; Vicky M Coyle; Michael R L Stratford; Lisa K Folkes; Richard Eastell; Claire Barton; Paul Jones; Shamim Kazmi-Stokes; Helen Turner; Sarah Halford; Adrian L Harris; Mark R Middleton
Journal:  Br J Cancer       Date:  2018-02-13       Impact factor: 7.640

6.  Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

Authors:  S Postel-Vinay; H-T Arkenau; D Olmos; J Ang; J Barriuso; S Ashley; U Banerji; J De-Bono; I Judson; S Kaye
Journal:  Br J Cancer       Date:  2009-05-05       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.